Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

(Reuters) -CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with ...

NasdaqGS:BNTX 1 Year Share Price vs Fair Value Explore BioNTech's Fair Values from the Community and select ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...

BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the ...